{
  "denotations": [
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 22,
        "end": 26
      }
    },
    {
      "id": "T3",
      "obj": "Disease",
      "span": {
        "begin": 166,
        "end": 169
      }
    },
    {
      "id": "T4",
      "obj": "Chemical",
      "span": {
        "begin": 199,
        "end": 211
      }
    },
    {
      "id": "T5",
      "obj": "Chemical",
      "span": {
        "begin": 22,
        "end": 31
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 84,
        "end": 88
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 84,
        "end": 93
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "28258422_9",
  "text": "The adverse events of EGFR -TKI rechallenge were tolerable , but one case receiving EGFR -TKI rechallenge with the suspected drug exhibited the recurrence of grade 3 ILD after the discontinuation of prednisolone ."
}
